**CASE REPORT**

Regression of fundic gland polyps following acquisition of *Helicobacter pylori*

N Watanabe, H Seno, T Nakajima, S Yazumi, S Miyamoto, S Matsumoto, T Itoh, C Kawanami, K Okazaki, T Chiba

The prevalence of *Helicobacter pylori* infection is very low in patients with fundic gland polyps (FGPs) of the stomach. We report here two cases with multiple FGPs that regressed following new *H pylori* acquisition. Patient Nos I and II had multiple FGPs in normal fundic mucosa without inflammatory changes or atrophy. Both were not infected with *H pylori*. Following acquisition of *H pylori* infection, however, all FGPs in both patients completely disappeared except for one FGP in patient No I. Although the size of the remaining polyp in patient No I was greatly reduced after *H pylori* acquisition, it became enlarged again after eradication. Interestingly, in the remaining polyp, we found an activating β-catenin gene mutation whereas no such mutations were detected in FGPs of patient No II. Thus *H pylori* infection may have an inhibitory effect on the development of FGPs.

Hyperplastic gastric polyps, which are characterised by hyperplasia of the foveolar epithelium, often develop in *Helicobacter pylori* infected gastric mucosa. In contrast, fundic gland polyps (FGPs), which are composed of fundic glands with disordered architecture and microcysts, frequently develop in the normal fundic mucosa. Interestingly, the prevalence of *H pylori* infection in patients with FGPs is extremely low. Thus *H pylori* infection does not appear to be involved in the development of FGPs. FGPs have generally been regarded as non-neoplastic lesions, either hamartomatous or hyperplastic in nature. However, recent studies have demonstrated somatic alterations of two genes in FGPs. Firstly, sporadic FGPs have somatic activating mutations of the β-catenin gene. Here we report two cases of multiple FGPs of a sporadic form that regressed following *H pylori* acquisition. Notably, we found that a somatic mutation of the β-catenin gene in one FGP in one patient, the size of which was markedly reduced after *H pylori* acquisition, was enlarged following eradication of *H pylori*.

**CASE REPORTS**

**Patient No I**

A 71 year old man underwent gastrointestinal endoscopy in February 1999 because of abdominal discomfort. Endoscopy demonstrated 15 recognisable polyps in the gastric corpus (fig 1A). Biopsies revealed that the polyps consisted of fundic gland hyperplasia with microcysts, the typical morphology of FGPs (fig 1B). Neither active gastritis nor atrophic changes of the fundic glands was detected. Results of both the rapid urease test and immunohistological staining for *H pylori* were negative. Serum antibody to *H pylori* was also negative. A colonoscopic examination performed one month later showed entirely normal colon, ruling out FAP. However, follow up endoscopy one year later demonstrated disappearance of all FGPs except for one polyp, the size of which was markedly reduced, in association with diffuse erythematous fundic mucosa (fig 1C). Biopsies showed chronic inflammatory changes in the corpus and antrum. *H pylori* acquisition was confirmed by culture, rapid urease test, immunohistological staining, and elevated serum IgG to *H pylori*. In addition, the remaining polyp was characterised by oedematous changes and neutrophilic infiltration concentrated in the foveolar compartment. Moreover, the remaining polyp showed disappearance of cystic dilatation of glandular ducts with concomitant appearance of elongation of foveolar epithelium (fig 1D). *H pylori* eradication was performed with lanzoprazole, amoxicillin, and clarithromycin.

Two months after completion of eradication therapy, follow up endoscopy showed no recurrence of polyps (fig 1E). Biopsy demonstrated marked reduction of active inflammation in the antral and corpus mucosa, including the remaining polyp (fig 1F). Biopsy and culture for *H pylori* and the urea breath test showed clearance of *H pylori*. Serum gastrin, pepsinogen I, and pepsinogen II levels were decreased. However, on follow up endoscopy six months after completion of eradication therapy, enlargement of the remaining polyp was noted (fig 1G). Polyp biopsies revealed hyperplasia of the fundic glands with microcysts (fig 1H), showing typical FGP morphology, and resolution of gastritis without atrophy was again confirmed. At 18 months after *H pylori* eradication, endoscopy again detected the remaining polyp, while no recurrence of other polyps. During his clinical course he has not received any specific medication except those for *H pylori* eradication.

**Patient No II**

A 42 year old woman underwent gastrointestinal endoscopy in July 1998 because of iron deficiency anaemia. She had been treated with oral administration of ferrous sulphate for two months. Endoscopy demonstrated 25 polyps in the corpus without any sign of gastritis (fig 2A). Biopsies revealed the polyps to consist of fundic gland hyperplasia with microcysts (fig 2B). Neither chronic inflammatory change nor atrophy was detected. Absence of *H pylori* was confirmed by the rapid urease test and immunohistological staining for *H pylori*. Serum antibody for *H pylori* was also negative. Two months later, colonoscopic examination showed entirely normal colon, ruling out FGPs associated with familial FAP. Endoscopic findings of the stomach one year later were unchanged. Two years after the first examination however, endoscopy demonstrated diffuse erythematous fundic mucosa with disappearance of all of the FGPs (fig 2C). Biopsies showed chronic inflammation without atrophy.

**Abbreviations:** FGP, fundic gland polyps; FAP, familial adenomatous polyposis; GSK-3β, glycogen synthase kinase 3β.
inflammatory changes in the corpus and antrum (fig 2D), and 
H pylori acquisition was confirmed. 
H pylori eradication therapy was performed as described in patient No I. Two months after completion of eradication therapy, follow up endoscopy demonstrated no recurrence of FGPs (fig 2E) and biopsies revealed resolution of gastritis and hyperplastic change of the fundic glands (fig 2F). Clearance of 
H pylori was confirmed. Ten months after completion of eradication, endoscopy demonstrated enlargement of the remaining polyp [arrow] (G). Biopsy of the polyp revealed hyperplasia of the fundic glands with microcysts, suggesting FGP morphology [H]. Endoscopic photographs (top) show the same view in the corpus. (Haematoxylin-eosin staining; original magnifications: lower panels 100×.)

DISCUSSION

In our two patients with FGPs, we found no colonisation of 
H pylori. Moreover, neither corpus gastritis nor atrophy was observed. On follow up endoscopy however, we found that they were newly infected with 
H pylori and developed chronic active gastritis in the corpus and antrum. Interestingly, the development of corpus gastritis by 
H pylori acquisition in these patients was associated with disappearance of FGPs except for one polyp in patient No I. These findings strongly suggest that FGPs were regressed by 
H pylori acquisition with the development of active corpus gastritis.

The precise mechanism for regression of FGPs by 
H pylori acquisition remains unknown at present. FGPs are usually defined as hyperplasia of the fundic glands as well as shortened foveolae. In contrast, 
H pylori infection induces development of fundic gland atrophy. At the same time, 
H pylori infection occasionally induces foveolar hyperplasia—for example, giant foveolar gastritis. As stem cells in the isthmus of the fundic mucosa can give rise to both foveolar mucous pit cell lineage and fundic glandular cell lineage, it may be interesting to speculate that acquired 
H pylori infection in our patients altered the direction of the differentiation process of FGPs, which disappeared after 
H pylori acquisition, did not have such mutations in patient No I. Moreover, we could not detect 
β-catenin gene mutations from any FGP in patient No II, which completely regressed after 
H pylori acquisition. In both patients, no 
β-catenin gene mutation was detected in the non-polypoidal normal fundic mucosa.

Mutation analysis of the 
β-catenin gene

A recent report has revealed that sporadic FGPs possess 
β-catenin gene mutations at glycogen synthase kinase 3β (GSK-3β) phosphorylation sites. Therefore, we examined whether FGPs in our two patients had 
β-catenin gene mutations. Genomic DNA was extracted from formalin fixed paraffin embedded biopsy specimens of FGPs and non-polypoidal normal fundic mucosa, and a 200 bp fragment of exon 3 of the 
β-catenin gene encompassing GSK-3β phosphorylation sites was amplified by polymerase chain reaction and sequenced directly, as described previously, with slight modifications. In the FGP of patient No I, that remained even after 
H pylori acquisition, direct sequencing analysis showed 1 bp missense mutation (TCT→TTT, Ser→Phe) at codon 37, one of the serine/threonine residues at GSK-3β phosphorylation sites, both before and after 
H pylori acquisition. In contrast, other FGPs, which disappeared after 
H pylori infection, did not have such mutations in patient No I. Moreover, we could not detect 
β-catenin gene mutations from any FGP in patient No II, which completely regressed after 
H pylori acquisition. In both patients, no 
β-catenin gene mutation was detected in the non-polypoidal normal fundic mucosa.
the fundic gland progenitor cells in the FGPs from glandular cell lineage towards pit cell lineage. Our finding that, in addition to elimination of almost all FGPs after Helicobacter pylori eradication, endoscopy demonstrated resolution of erythematous change of the fundic mucosa and no recurrence of polyps (E). On histological examination, gastritis was reduced and the fundic glands had hyperplastic changes (F). Endoscopic photographs (top) show the same view in the corpus. (Haematoxylin-eosin staining; original magnifications: lower panels ×100.)

The natural history of FGPs has not been clearly established. Some investigators have reported a decrease not only in size but also in the number of polyps during observation whereas others have documented an increase in size as well as number. Thus how Helicobacter pylori infection and/or alterations in the β-catenin gene influence(s) the natural history of FGPs remains to be determined.

In summary, we have described multiple FGPs regression following Helicobacter pylori acquisition with concomitant appearance of corpus gastritis in two patients, indicating an inhibitory action of Helicobacter pylori infection on the development and expansion of FGPs. These findings are in agreement with the fact that the prevalence of Helicobacter pylori infection is very low in patients with FGPs. As we investigated only two cases, a further study in a large number of patients with FGPs is required to clarify the roles of β-catenin gene mutation and Helicobacter pylori infection in the clinical course of FGPs.

Authors’ affiliations
N Watanabe, H Seno, T Nakajima, S Yazumi, S Miyamoto, S Matsumoto, T Itoh, C Kawanami, K Okazaki, T Chiba, Department of Gastroenterology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawara-cho, Sakyo-ku, Kyoto 606-8507, Japan
Correspondence to: Dr T Chiba, Department of Gastroenterology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawara-cho, Sakyo-ku, Kyoto 606-8507, Japan; chiba@kuhp.kyoto-u.ac.jp
Accepted for publication 4 January 2002

REFERENCES


